Dr. Lal PathLabs has announced key decisions following its board meeting on April 30, 2026, including financial results, a dividend declaration, and strategic expansions. The company reported its audited standalone and consolidated financial results for the quarter and financial year ending March 31, 2026.
The board has recommended a final dividend of ₹4 per equity share, representing 40% of the face value of ₹10 each, for the financial year ended March 31, 2026. This dividend is subject to approval at the upcoming Annual General Meeting (AGM), with a record date set for June 26, 2026. The dividend will be credited within 30 days of member approval.
In a strategic move, Dr. Lal PathLabs will acquire a 100% stake in Shahbazkers Diagnostic Centre Private Limited (SDCPL), making it a wholly owned subsidiary. This acquisition aligns with the company’s growth strategy and expansion in diagnostic services.
Additionally, the company plans to incorporate a wholly owned subsidiary in Dubai, United Arab Emirates, named Dr. Lal PathLabs FZCO, pending regulatory approvals.
The board also approved the re-appointment of (Hony) Brig. Dr. Arvind Lal, Padma Shri, as Executive Chairman and Whole-Time Director for five years starting April 1, 2027, and Mr. Rajit Mehta as a Non-Executive Independent Director for five years from July 27, 2026, both subject to AGM approval.
Dr. Reena Nakra and Dr. Saloni Khera have been designated as Senior Management Personnel, effective April 30, 2026. The company also re-appointed Ernst & Young LLP as Internal Auditors and A.G. Agarwal & Associates as Cost Auditors for the financial year 2026-27.
Furthermore, Dr. Lal PathLabs allotted 82,750 equity shares under its Employee Stock Option Plan 2022, increasing its paid-up equity share capital to ₹1,67,63,77,700.
The 32nd AGM is scheduled for July 25, 2026, via video conferencing.
Disclaimer: This article is based on a regulatory filing submitted to the National Stock Exchange of India (NSE).